Read about our ongoing efforts to help address the opioid crisis here

Learn more about our partnership with the Prescription Drug Safety Network and year-one results from the Prescription Drug Safety prevention curriculum here

RECENT NEWS

Purdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose

NAL1002 study will examine pharmacokinetics, safety and tolerability of nalmefene HCl Company will not profit from nalmefene HCl injection Stamford, Conn. – June 6, 2019 – Purdue Pharma L.P. today…

Eisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant

WOODCLIFF LAKE, N.J. and STAMFORD, Conn. – April 30, 2019 – Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue’s rights to the worldwide collaboration for the…

FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose

Committed to advancing solutions to the opioid addiction crisis, Purdue will not profit from nalmefene HCl Stamford, Conn. – April 24, 2019 – Purdue Pharma L.P. today announced that the U.S. Food…